Join the club for FREE to access the whole archive and other member benefits.

Alex Blyth

Founder and Chief Executive Officer of LIfT BioSciences

Serial entrepreneur with 15 years’ experience in commercialising novel biopharma assets and strategy consulting, having advised teams and led the strategic planning for bringing to market over 50 assets for companies like Pfizer, Allergan, abbVie, Amgen, Shire, Takeda, GSK & Sanofi. Founded the company after losing his mother to Pancreatic Cancer, and seeing a new way to beat cancer by utilising the innate immune system.

Visit website: https://www.liftbiosciences.com/our-staff

 alex-blyth-a33b7a

 alexblyth33

See also: Company LIfT BioSciences - Biotechnology company that develops a portfolio of potentially life-saving immuno-oncology cell therapies

Details last updated 01-May-2020

Alex Blyth is also referenced in the following:

LIfT BioSciences

Biotechnology company that develops a portfolio of potentially life-saving immuno-oncology cell therapies

Alex Blyth News

New immunotherapy shows promise in fighting resistant pancreatic cancer

New immunotherapy shows promise in fighting resistant pancreatic cancer

Labiotech - 04-May-2023

IMAN therapy targets tumours and activates the immune system against tough-to-treat cancers

LIfT BioSciences cell therapy infiltrates pancreatic tumour in mice models

LIfT BioSciences cell therapy infiltrates pancreatic tumour in mice models

LIfT BioSciences - 09-Nov-2020

N-LIfT is an allogenic cell therapy which recruits patient's own immune cells against cancers

Radical new cancer treatment to be trialled next year

Radical new cancer treatment to be trialled next year

ITV News - 24-Nov-2017

Uses cancer-killing cells from people with the strongest immune systems. Neutrophil cells form p...